Gabriel Cedeno BSN RN Selected to NCLEX Item Development Panel 

Translate to Spanish or other 102 languages!

Gabriel Cedeno BSN RN, a distinguished educator in the field of nursing at Rio Grande Valley College, has been honored with a significant appointment as a volunteer item developer for the National Council of State Boards of Nursing Licensure Examination (NCLEX®). This prestigious selection, approved by the Texas Board of Nursing and facilitated by the NCSBN, headquartered in Chicago, underscores Gabriel's dedication and expertise in nursing education. 
Gabriel Cedeno BSN RN, a distinguished educator in the field of nursing at Rio Grande Valley College, has been honored with a significant appointment as a volunteer item developer for the National Council of State Boards of Nursing Licensure Examination (NCLEX®). This prestigious selection, approved by the Texas Board of Nursing and facilitated by the NCSBN, headquartered in Chicago, underscores Gabriel’s dedication and expertise in nursing education. 
- Advertisement -

Gabriel Cedeno BSN RN, a distinguished educator in the field of nursing at Rio Grande Valley College, has been honored with a significant appointment as a volunteer item developer for the National Council of State Boards of Nursing Licensure Examination (NCLEX®). This prestigious selection, approved by the Texas Board of Nursing and facilitated by the NCSBN, headquartered in Chicago, underscores Gabriel’s dedication and expertise in nursing education. 

The NCLEX-RN® and NCLEX-PN® are paramount in evaluating the competencies of nursing candidates across the United States and parts of Canada. Gabriel Cedeno’s involvement in the item development panel, held in Chicago, IL, from December 12-16, 2023, reflects his profound knowledge and experience in nursing, particularly in his clinical specialty of Pediatrics. 

Gabriel’s journey in nursing is one of perseverance and passion. Originally from Puerto Rico, he embarked on his educational odyssey with a Bachelor’s Degree in Literature and Theater in 2004, a pursuit driven by the lack of support in his initial nursing aspirations. However, his inherent calling for nursing led him to acquire a Vocational Nursing Certification and License in 2011, followed by a commendable journey to a Bachelor of Science in Nursing in 2016. 

- Advertisement -

Since joining Rio Grande Valley College in 2019, Gabriel has been instrumental as the Lead Pediatric Nurse Educator in the Vocational Nursing Program. His journey from an unfulfilled dream to touching the lives of hundreds of patients and students exemplifies his unwavering dedication to nursing. His story is not just one of professional achievement but of inspiring transformation and relentless pursuit of one’s calling. 

Gabriel’s selection by the NCSBN is a testament to his exceptional skill set and an acknowledgment of his significant contributions to nursing education. His role in shaping future nurses through the NCLEX is pivotal in ensuring the highest standards of nursing care and education. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.
- Advertisement -